The toxicity of diethylaminoreserpine (DL-1 52) to cells of transplantable mouse tumours has been investigated in this laboratory using in vivo and in vitro systems (Lehnert, 1980 (Lehnert, , 1982a (Lehnert, , 1982b For extraction of DL-152, the tumour was homogenized in 7vol of 0.01 NHC1 and the supernatant extracted with 4 vol of chloroform, the chloroform phase was washed twice with dilute acid and evaporated to dryness. The efficiency of this extraction procedure was -70%. The residue was dissolved in a small volume of methanol and 20 pl samples chromatographed using a chromosorb C-18 column; the mobile phase was 60% acetonitrile, 37.5% water, 2.5% glacial acetic acid and 1.5gl-1 heptane sulfonic acid. Propriophenone was used as an internal standard. Reduction in the number of clonogenic cells per tumour following administration of DL-152 to the host resulted from two factors: a reduction in the number of viable cells recovered from the tumour and a decrease in the plating efficiency of these cells. These two effects are shown separately in Figures l(a) and l(b) , while the overall reduction in numbers of clonogenic tumour cells following DL-152 injection is shown in Figure l(c) .
The toxicity of diethylaminoreserpine (DL-1 52) to cells of transplantable mouse tumours has been investigated in this laboratory using in vivo and in vitro systems (Lehnert, 1980 (Lehnert, , 1982a (Lehnert, , 1982b . It was found that for short exposures to DL-152, hypoxic tumour cells are more sensitive to the drug than are aerated cells, while in vitro hypoxic cells are killed by lower concentrations of the drug than are aerated cells. For both flank and lung tumours, sensitivity to the drug increases with increasing tumour size, however the presence of an hypoxic fraction is not a prerequisite for the cytotoxic action of the drug. These results support the conclusion that hypoxia sensitises cells to the toxic effects of DL-152 but is not essential for the expression of toxicity. On this basis it was predicted that although not a radiosensitiser per se (Lehnert et al., 1981 ) DL-152 might be used effectively in conjunction with radiotherapy, if administration were timed to reduce the radioresistant hypoxic cell population to a minimum prior to irradiation. In the present study, the validity of this prediction was investigated by measurement of the hypoxic fraction of the KHT tumour at various times after drug injection. In addition, the extent of cell kill was correlated with the drug concentration in the tumour.
DL-152 was obtained from Laboratoires Lefrancq, Romainville, France. DL-152 (320 mg kg -1) was injected i.p. in 0.1 ml saline. Control mice were injected with 0.1 ml saline and the tumour processed in parallel with the DL-152 treated group.
The KHT fibrosarcoma (Kallman et al., 1967) was grown in male C3H mice. Tumours were implanted intramuscularly by injection of 2.5 x 105 cells in a volume of 0.05ml into the distal portion of the gastrocnemius muscle of one hind leg. The colony forming ability of KHT cells was assayed by the in vitro agar plating technique described by Thomson & Rauth (1974) as modified by Hill et al. (1979) . Tumour size was determined by measurement of the diameter of the tumour-bearing leg. Values were converted to tumour weights by reference to a previously prepared calibration curve relating leg diameter to tumour weight.
The size of the hypoxic fraction was determined for tumours of approximately 0.5g by comparison of survival curves of tumours irradiated in situ in air-breathing and nitrogen-asphyxiated mice, a method originally described by Van Putten & Kallman (1968) . Straight lines on a semi-log plot were fitted to data points between 15 and 30Gy by linear regression analysis. The hypoxic fractions were calculated from the displacement of the terminal portions of the survival curves for tumour cells from air-breathing and nitrogen-asphyxiated animals. The actual value assigned to the hypoxic fraction was the ratio of Surviving Fractions at 25 Gy using values read off the regression line.
For extraction of DL-152, the tumour was homogenized in 7vol of 0.01 NHC1 and the supernatant extracted with 4 vol of chloroform, the chloroform phase was washed twice with dilute acid and evaporated to dryness. The efficiency of this extraction procedure was -70%. The residue was dissolved in a small volume of methanol and 20 pl samples chromatographed using a chromosorb C-18 column; the mobile phase was 60% acetonitrile, 37.5% water, 2.5% glacial acetic acid and 1.5gl-1 heptane sulfonic acid. Propriophenone was used as an internal standard. Reduction in the number of clonogenic cells per tumour following administration of DL-152 to the host resulted from two factors: a reduction in the number of viable cells recovered from the tumour and a decrease in the plating efficiency of these cells. These two effects are shown separately in It is apparent that reduction in the number of cells recovered is the major factor in reducing tumour cell numbers. Also shown in Figures l(a), 1(b) and 1(c) are results obtained when tumour bearing animals are sacrificed by nitrogen asphyxiation and excision of the tumour is delayed for 15 min after sacrifice. At all times after drug injection, this period of acute hypoxia enhances the cytotoxic effects of the drug and again the effect is produced largely by reduction of the number of viable cells recovered. Figure  1 (c) that although the most rapid fall in tumour cell numbers occurs during the first hour after drug administration, a decline in cell number continues for at least 24 h after injection. This prolonged period over which the effects of the drug persist is presumably related to the slow rate at which DL-152 is cleared from the tumour. Metabolism of DL-152 may resemble that of reserpine in some respects, following the injection of the latter compound, low concentrations of the drug are maintained in various tissues over a prolonged period (Stitzel, 1976) . It is unlikely that the metabolism of DL-152 resembles that of reserpine in all respects however, since the presence of a polar side chain on DL-152 would presumably reduce the high lipophilicity which characterizes reserpine.
The preferential toxicity of DL-152 towards -hypoxic cells which had been demonstrated in vivo and in vitro suggested that reduction in the size of the hypoxic fraction would occur in tumours exposed to the drug. To test this hypothesis radiation survival curves for aerated and hypoxic KHT tumour cells irradiated in situ were prepared. For controls (Figure 2 ) the ratio of Surviving Fractions for the terminal portion of the survival curves for aerated and hypoxic cells was 0.1 1, giving an hypoxic fraction of 11% for 0.5 g intramuscular tumours. Figure 3 shows results obtained at one hour after injection of 152; at this time, both aerated and hypoxic cells show higher survival (relative to drug treated controls) than do cells from control tumours. Radioprotection at short times after DL-152 injection has been previously observed for flank (Lehnert et al., 1981) . It should be noted that while the Surviving Fraction for DL-152 treated tumour cells relative to drug treated non-irradiated cells is elevated, the overall number of clonogenic cells at this time is reduced (see Figure 1) . The hypoxic fraction for tumours at one hour after injection was calculated to be 15%, larger than that of control.
At 8, 16, and 24h after DL-152 injection ( Figure  4 ) results are not complicated by drug-induced changes in radiation response, and at all three times there is a decrease in the size of the hypoxic fraction, the lowest value (4%) being seen at 8h after injection. The sizes of the hypoxic fractions for tumours assayed at various times after DL-152 injection are summarized in Table I . Dose (Gy) does not differ significantly from that for non-drug treated tumours (by the same criteria as above), however the Surviving Fraction for drug-treated aerated cells is significantly less than that for nondrug treated cells (P<0.05) with the result that the calculated hypoxic fraction for drug-treated tumours is less than that of control. If these changes were the result of an increased radiosensitivity for drug-treated hypoxic cells the extent of the change would presumably be radiation dose-dependent. In fact the ratio of Surviving Fractions remains quite constant over the dose range 15-30 Gy (Figure 4(b) ). The most likely explanation of these observations is that the proportion of hypoxic cells in the tumour has been reduced during 16h exposure to the drug. The fact that the hypoxic fraction is reduced between 8 and 24h post-injection and possibly for a longer period suggests that for combined treatment of tumours with and radiation, the most effective protocol would schedule radiation treatment for the post-injection period when the hypoxic fraction is minimal. Experiments are being done to determine the effectiveness of combined treatment at these times.
